

Table - 7: Course of study for M. Pharm. (Regulatory Affairs)

Course Code	Course	Credit Hours	Credit Points	Hrs./wk	Marks
Semester I					
MRA 101T	Good Regulatory Practices	4	4	4	100
MRA 102T	Documentation and Regulatory Writing	4	4	4	100
MRA 103T	Clinical Research Regulations	4	4	4	100
MRA 104T	Regulations and Legislation for Drugs & Cosmetics, Medical Devices, Biologicals & Herbals, and Food & Nutraceuticals In India and Intellectual Property Rights	4	4	4	100
MRA 105P	Regulatory Affairs Practical I	12	6	12	150
	Seminar/Assignment	7	4	7	100
	Total	35	26	35	650
Semester II					
MRA 201T	Regulatory Aspects of Drugs & Cosmetics	4	4	4	100
MRA 202T	Regulatory Aspects of Herbal & Biologicals	4	4	4	100
MRA 203T	Regulatory Aspects of Medical Devices	4	4	4	100
MRA 204T	Regulatory Aspects of Food & Nutraceuticals	4	4	4	100
MRA 205P	Regulatory Affairs Practical II	12	6	12	150
	Seminar/Assignment	7	4	7	100
	Total	35	26	35	650

Table - 12: Course of study for M. Pharm. III Semester
(Common for All Specializations)

Course Code	Course	Credit Hours	Credit Points
MRM 301T	Research Methodology and Biostatistics*	4	4
-	Journal club	1	1
-	Discussion / Presentation (Proposal Presentation)	2	2
-	Research Work	28	14
Total		35	21

* Non University Exam

Table - 13: Course of study for M. Pharm. IV Semester
(Common for All Specializations)

Course Code	Course	Credit Hours	Credit Points
-	Journal Club	1	1
-	Research Work	31	16
-	Discussion/Final Presentation	3	3
Total		35	20

Table - 14: Semester wise credits distribution

Semester	Credit Points
I	26
II	26
III	21
IV	20
Co-curricular Activities (Attending Conference, Scientific Presentations and Other Scholarly Activities)	Minimum=02 Maximum=07*
Total Credit Points	Minimum=95 Maximum=100*

*Credit Points for Co-curricular Activities

SEMESTER II
REGULATORY ASPECTS OF DRUGS & COSMETICS
(MRA 201T)

Scope

This course is designed to impart the fundamental knowledge on the drug development process, regulatory requirements for approval of new drugs, drug products and cosmetics in regulated and semi-regulated countries. It prepares the students to learn in detail on the regulatory requirements, documentation requirements, and registration procedures for marketing the drug products and cosmetics in regulated and semi-regulated countries.

Objectives

Upon completion of the course, the student shall be able to know

- process of drug discovery and development and generic product development
- regulatory approval process and registration procedures for API and drug products in US, EU
- Cosmetics regulations in regulated and semi-regulated countries
- A comparative study of India with other global regulated markets

Theory

60 Hrs

- | | | |
|----|---|-----------|
| 1. | USA & CANADA: Organization structure and functions of FDA. Federal register and Code of Federal Regulations (CFR), History and evolution of United States Federal, Food, Drug and Cosmetic Act (FDCA), Hatch Waxman act and Orange book, Purple book, Drug Master Files (DMF) system in US, Regulatory Approval Process for Investigational New Drug (IND), New Drug Application (NDA), Abbreviated New Drug Application (ANDA), Supplemental New Drug Application (SND); Regulatory requirements for Orphan drugs and Combination Products, Changes to an approved NDA / ANDA. Regulatory considerations for manufacturing, packaging and labeling of pharmaceuticals in USA. Legislation and regulations for import, manufacture, distribution and sale of cosmetics in USA and Canada. | 12
Hrs |
| 2 | European Union & Australia: Organization and structure of EMA & EDQM, General guidelines, Active Substance Master Files (ASMF) system in EU, Content and approval process of IMPD, Marketing Authorization procedures in EU (Centralized procedure, | 12
Hrs |

Decentralized procedure, Mutual recognition procedure and National Procedure). Regulatory considerations for manufacturing, packaging and labeling of pharmaceuticals in EU, Eudralex directives for human medicines, Variations & extensions, Compliance of European Pharmacopoeia (CEP)/ Certificate of Suitability (CoS), Marketing Authorization (MA) transfers, Qualified Person (QP) in EU. Legislation and regulations for import, manufacture, distribution and sale of cosmetics in European Union & Australia.

- 3 Japan: Organization of the PMDA, Pharmaceutical Laws and regulations, types of registration applications, DMF system in Japan, drug regulatory approval process, Regulatory considerations for manufacturing, packaging and labeling of pharmaceuticals in Japan, Post marketing surveillance in Japan. Legislation and regulations for import, manufacture, distribution and sale of cosmetics in Japan 12 Hrs
- 4 Emerging Market: Introduction, Countries covered, Study of the world map, study of various committees across the globe (ASEAN, APEC, EAC, GCC, PANDRH, SADC) 12 Hrs
WHO: WHO, GMP, Regulatory Requirements for registration of drugs and post approval requirements in WHO through prequalification programme, Certificate of Pharmaceutical Product (CoPP) - General and Country Specific (South Africa, Egypt, Algeria and Morocco, Nigeria, Kenya and Botswana)
- 5 Brazil, ASEAN, CIS and GCC Countries: 12 Hrs
ASIAN Countries: Introduction to ACTD, Regulatory Requirements for registration of drugs and post approval requirements in China and South Korea & Association of Southeast Asian Nations (ASEAN) Region i.e. Vietnam, Malaysia, Philippines, Singapore and Thailand.
CIS (Commonwealth Independent States): Regulatory pre-requisites related to Marketing authorization requirements for drugs and post approval requirements in CIS countries i.e. Russia, Kazakhstan and Ukraine
GCC (Gulf Cooperation Council) for Arab states: Regulatory pre-requisites related to Marketing authorization requirements for drugs and post approval requirements in Saudi Arabia and UAE
Legislation and regulations for import, manufacture, distribution and sale of cosmetics in Brazil, ASEAN, CIS and GCC Countries.

REFERENCES :

1. Generic Drug Product Development, Solid Oral Dosage forms, Leon Shargel and Isader Kaufer, Marcel Dekker series, Vol.143
2. The Pharmaceutical Regulatory Process, Edited by Ira R. Berry Marcel Dekker Series, Vol.144
3. The Pharmaceutical Regulatory Process, Second Edition Edited by Ira R. Berry and Robert P. Martin, Drugs and the Pharmaceutical Sciences, Vol.185 Informa Health care Publishers.
4. New Drug Approval Process: Accelerating Global Registrations By Richard A Guarino, MD, 5th edition, Drugs and the Pharmaceutical Sciences, Vol.190.
5. Guidebook for drug regulatory submissions / Sandy Weinberg. By John Wiley & Sons. Inc.
6. Drugs: From Discovery to Approval, Second Edition By Rick Ng
7. New Drug Development: A Regulatory Overview, Eighth Edition By Mark Mathieu
8. Pharmaceutical Risk Management By Jeffrey E. Fetterman, Wayne L. Pines and Gary H. Slatko
9. Preparation and Maintenance of the IND Application in eCTD Format By William K. Sietsema
10. Country Specific Guidelines from official websites.
11. http://www.who.int/medicines/areas/quality_safety/regulation_legislation/ListMRAWbsites.pdf
12. Roadmap to an ASEAN economic community Edited by Denis Hew. ISEAS Publications, Singapore 2005, ISBN981-230-347-2
13. ASEAN, Rodolfo G. Severino, ISEAS Publications, Singapore 2005, ISBN 978-981-230-750-7
14. Building a Future with Brics: The Next Decade for Offshoring, Mark Kobayashi-Hillary, Springer
15. Outsourcing to India: The Offshore Advantage, Mark Kobayashi-Hillary, Springer Trade performance and Regional Integration of the CIS Countries, Lev Freinkman,
16. The world Bank, Washington, DC, ISBN: 0-8212-5896-0
17. Global Pharmaceutical Policy: Ensuring Medicines for Tomorrow's World ByFrederick M. Abbott, Graham Dukes, Maurice Nelson Graham Dukes 139
18. The Gulf Cooperation Council: A Rising Power and Lessons for ASEAN by Linda Low and Lorraine Carlos Salazar (Nov 22, 2010)
19. Doing Business in the Asean Countries, Balbir Bhasin, Business Expert Press ISBN:13:978-1-60649-108-9
20. Realizing the ASEAN Economic Community: A Comprehensive Assessment, Michael G Plummer (Editor), Chia Siow Yue (Editor), Institute of South east asian studies, Singapore

REGULATORY ASPECTS OF HERBAL AND BIOLOGICALS (MRA 202T)

Scope

This course is designed to impart fundamental knowledge on Regulatory Requirements, Licensing and Registration, Regulation on Labelling of Biologics in India, USA and Europe

It prepares the students to learn in detail on Regulatory Requirements for biologics, Vaccines and Blood Products

Objectives

Upon the completion of the course the student shall be able to :

- Know the regulatory Requirements for Biologics and Vaccines
- Understand the regulation for newly developed biologics and biosimilars
- Know the pre-clinical and clinical development considerations of biologics
- Understand the Regulatory Requirements of Blood and/or Its Components Including Blood Products and label requirements

Theory

60 Hrs

1. India : Introduction, Applicable Regulations and Guidelines , 12 Hrs
Principles for Development of Similar Biologics, Data Requirements for Preclinical Studies, Data Requirements for Clinical Trial Application, Data Requirements for Market Authorization Application, Post-Market Data for Similar Biologics, Pharmacovigilance. GMP and GDP.
- 2 USA: Introduction to Biologics; biologics, biological and biosimilars, different biological products, difference between generic drug and biosimilars, laws, regulations and guidance on biologics/ biosimilars, development and approval of biologics and biosimilars (IND, PMA, BLA, NDA, 510(k), pre-clinical and clinical development considerations, advertising, labelling and packing of biologics 12 Hrs
- 3 European Union: Introduction to Biologics; directives, scientific guidelines and guidance related to biologics in EU, comparability/ biosimilarity assessment, Plasma master file, TSE/ BSE evaluation, development and regulatory approval of biologics (Investigational medicinal products and biosimilars), pre-clinical 12 Hrs

and clinical development considerations; stability, safety, advertising, labelling and packing of biologics in EU

- | | | |
|---|---|-----------|
| 4 | Vaccine regulations in India, US and European Union: Clinical evaluation, Marketing authorisation, Registration or licensing, Quality assessment, Pharmacovigilance, Additional requirements
Blood and Blood Products Regulations in India, US and European Union: Regulatory Requirements of Blood and/or Its Components Including Blood Products, Label Requirements, ISBT (International Society of Blood Transfusion) and IHN (International Haemovigilance Network) | 12
Hrs |
| 5 | Herbal Products: Quality, safety and legislation for herbal products in India, USA and European Union. | 12
Hrs |

REFERENCES

1. FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics, Douglas J. Pisano, David S. Mantus; Informa, 2008
2. Biological Drug Products: Development and Strategies; Wei Wang, Manmohan Singh; Wiley, 2013
3. Development of Vaccines: From Discovery to Clinical Testing; Manmohan Singh, Indresh K. Srivastava; Wiley, 2011
4. www.who.int/biologicals/en
5. www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/
6. www.ihn-org.com
7. www.isbtweb.org
8. Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India
9. www.cdsco.nic.in
10. www.ema.europa.eu > scientific guidelines > Biologics
11. www.fda.gov/biologicsbloodvaccines/guidancecomplianceinformation/ (Biologics) Regulatory Information

REGULATORY ASPECTS OF MEDICAL DEVICES (MRA 203T)

Scope

This course is designed to impart the fundamental knowledge on the medical devices and in vitro diagnostics, basis of classification and product life cycle of medical devices, regulatory requirements for approval of medical devices in regulated countries like US, EU and Asian countries along with WHO regulations. It prepares the students to learn in detail on the harmonization initiatives, quality and ethical considerations, regulatory and documentation requirements for marketing medical devices and IVDs in regulated countries.

Objectives

Upon completion of the course, the student shall be able to know

- basics of medical devices and IVDs, process of development, ethical and quality considerations
- harmonization initiatives for approval and marketing of medical devices and IVDs
- regulatory approval process for medical devices and IVDs in India, US, Canada, EU, Japan and ASEAN
- clinical evaluation and investigation of medical devices and IVDs

Theory

60 Hrs

1. Medical Devices: Introduction, Definition, Risk based classification and Essential Principles of Medical Devices and IVDs. Differentiating medical devices IVDs and Combination Products from that of pharmaceuticals, History of Medical Device Regulation, Product Lifecycle of Medical Devices and Classification of Medical Devices. IMDRF/GHTF: Introduction, Organizational Structure, Purpose and Functions, Regulatory Guidelines, Working Groups, Summary Technical Document (STED), Global Medical Device Nomenclature (GMDN). 12 Hrs
- 2 Ethics: Clinical Investigation of Medical Devices, Clinical Investigation Plan for Medical Devices, Good Clinical Practice for Clinical Investigation of medical devices (ISO 14155:2011) 12 Hrs
Quality: Quality System Regulations of Medical Devices: ISO 13485, Quality Risk Management of Medical Devices: ISO 14971, Validation and Verification of Medical device, Adverse Event Reporting of Medical device

- | | | |
|---|--|-----------|
| 3 | USA: Introduction, Classification, Regulatory approval process for Medical Devices (510k) Premarket Notification, Pre-Market Approval (PMA), Investigational Device Exemption (IDE) and In vitro Diagnostics, Quality System Requirements 21 CFR Part 820, Labeling requirements 21 CFR Part 801, Post marketing surveillance of MD and Unique Device Identification (UDI). Basics of In vitro diagnostics, classification and approval process. | 12
Hrs |
| 4 | European Union: Introduction, Classification, Regulatory approval process for Medical Devices (Medical Device Directive, Active Implantable Medical Device Directive) and In vitro Diagnostics (In Vitro Diagnostics Directive), CE certification process. Basics of In vitro diagnostics, classification and approval process. | 12
Hrs |
| 5 | ASEAN, China & Japan: Medical Devices and IVDs, Regulatory registration procedures, Quality System requirements and clinical evaluation and investigation. IMDRF study groups and guidance documents. | 12
Hrs |

REFERENCES

1. FDA regulatory affairs: a guide for prescription drugs, medical devices, and biologics by Douglas J. Pisano, David Mantus.
2. Medical Device Development: A Regulatory Overview by Jonathan S. Kahan
3. Medical Product Regulatory Affairs: Pharmaceuticals, Diagnostics, Medical Devices by John J. Tobin and Gary Walsh
4. Compliance Handbook for Pharmaceuticals, Medical Devices and Biologics by Carmen Medina
5. Country Specific Guidelines from official websites.

**SUBJECT : REGULATORY ASPECTS OF FOOD & NUTRACEUTICALS
(MRA 204T)**

1. Nutraceuticals: Introduction, History of Food and Nutraceutical Regulations, Meaning of Nutraceuticals, Dietary Supplements, Prebiotics, Probiotics, Functional Foods, Medical Foods, Scope and Opportunities in Nutraceutical Market.

2 Global Aspects: WHO guidelines on nutrition. NSF International: It's Role in the Dietary Supplements and Nutraceuticals Industries, NSF Certification, NSF Standards for Food And Dietary Supplements. Good Manufacturing Practices for Nutraceuticals.

3 India: Food Safety and Standards Act, Food Safety and Standards Authority of India: Organization and Functions, Regulations for import, manufacture and sale of nutraceutical products in India, Types of Licenses in nutraceuticals, Application submission to FoSCoS portal, Recommended Dietary Allowances (RDA) in India.

4 USA: US FDA Food Safety Modernization Act, Dietary Supplement Health and Education Act. U.S. regulations for manufacture and sale of nutraceuticals and dietary supplements, Labelling Requirements and Label Claims for Dietary Supplements, Recommended Dietary Allowances (RDA) in the U.S

5 European Union: European Food Safety Authority (EFSA): Organization and Functions. EU Directives and regulations for manufacture and sale of nutraceuticals and dietary supplements. Nutrition labelling. European Regulation on Novel Foods and Novel Food Ingredients. Recommended Dietary Allowances (RDA) in Europe.

REFERENCES

1. Regulation of Functional Foods and Nutraceuticals: A Global Perspective by Clare M. Hasler (Wiley Online Library)
2. Nutraceutical and Functional Food Regulations in the United States and Around the World by Debasis Bagchi (Academic Press, Elsevier)
3. http://www.who.int/publications_guidelines_nutrition/en/
4. [http://www.europarl.europa.eu/RegData/etudes/STUD/2015/536324/IPOL_STU\(2015\)536324_EN.pdf](http://www.europarl.europa.eu/RegData/etudes/STUD/2015/536324/IPOL_STU(2015)536324_EN.pdf)
5. Handbook of Nutraceuticals by Yashwant Pathak (CRC Press)
6. Food Regulation: Law, Science, Policy and Practice by Neal D. Fortin (Wiley)
7. Country Specific Guidelines from official websites.

REGULATORY AFFAIRS PRACTICAL - II
(MRA 205P)

1. Case studies on
2. Change Management/ Change control. Deviations
3. Corrective & Preventive Actions (CAPA)
4. Documentation of raw materials analysis as per official monographs
5. Preparation of audit checklist for various agencies
6. Preparation of submission to FDA using eCTD software
7. Preparation of submission to EMA using eCTD software
8. Preparation of submission to MHRA using eCTD software
9. Preparation of Biologics License Applications (BLA)
10. Preparation of documents required for Vaccine Product Approval
11. Comparison of clinical trial application requirements of US, EU and India of Biologics
12. Preparation of Checklist for Registration of Blood and Blood Products
13. Registration requirement comparison study in 5 emerging markets (WHO) and preparing check list for market authorization
14. Registration requirement comparison study in emerging markets (BRICS) and preparing check list for market authorization
15. Registration requirement comparison study in emerging markets (China and South Korea) and preparing check list for market authorization
16. Registration requirement comparison study in emerging markets (ASEAN) and preparing check list for market authorization
17. Registration requirement comparison study in emerging markets (GCC) and preparing check list for market authorization
18. Checklists for 510k and PMA for US market
19. Checklist for CE marking for various classes of devices for EU
20. STED Application for Class III Devices
21. Audit Checklist for Medical Device Facility
22. Clinical Investigation Plan for Medical Devices